Coherus Oncology, Inc. (CHRS) Total liabilities 2016–2025
Coherus Oncology, Inc. (CHRS) total liabilities at each fiscal year-end, per SEC filings.
$197.3MFY2025 · since FY2016: $159.1M → $197.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $197.3M | -66.0% |
| FY2024 | $580.5M | -29.5% |
| FY2023 | $823.0M | +33.1% |
| FY2022 | $618.3M | +6.3% |
| FY2021 | $581.6M | +3.7% |
| FY2020 | $560.7M | +84.6% |
| FY2019 | $303.7M | +120.0% |
| FY2018 | $138.1M | +4.5% |
| FY2017 | $132.1M | -17.0% |
| FY2016 | $159.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice